BGNE Well Stocked, APVO On A Roll, GMED Hits ALL-time High

(RTTNews) - The following are some of the biotech stocks that made their way onto the Day's Gainers list of December 4, 2017.

GAINERS

1. BeiGene Ltd. (BGNE)

Gained 16.67% to close Monday's (Dec.4) trading at $94.50.

News: No news

Pipeline:

The Company's pipeline includes BGB-3111, BGB-A317 and BGB-290.

Clinical trials:

A pivotal phase II trial in China of BGB-3111 in relapsed/refractory mantle cell lymphoma; a global phase III trial of BGB-3111 compared to bendamustine and rituximab in treatment-naïve chronic lymphocytic leukemia / small lymphocytic lymphoma patients; a global pivotal phase II trial of BGB-3111 in combination with GAZYVA in relapsed or refractory follicular lymphoma patients; and a pivotal phase II trial in China of BGB-3111 in Waldenström's macroglobulinemia; a global phase III trial of BGB-3111 compared to bendamustine and rituximab (BR) in treatment-naïve chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) patients and a global pivotal phase II trial of BGB-3111 in combination with GAZYVA in relapsed or refractory follicular lymphoma (FL) patients are underway.

BGB-A317 is under a phase II trial in China in relapsed/refractory classical Hodgkin's lymphoma; a global phase 1a/1b trial in advanced tumors; phase III trial in China as a second- or third-line treatment for patients with advanced lung cancer; pivotal phase II trial in China in previously treated, PD-L1-positive, locally advanced or metastatic urothelial cancer; phase II trial in China in combination with chemotherapy as a first-line treatment for patients with advanced lung cancer; and a phase II trial in China in combination with chemotherapy as a first-line treatment for patients with locally advanced or metastatic esophageal, gastric, or gastroesophageal junction carcinoma.

BGB-290 is under a global phase I trial in combination with temozolomide in locally advanced or metastatic solid tumors, and under a global Phase 1b/2 trial in combination with radiation therapy and/or temozolomide in glioblastoma.

Near-term catalysts:

-- Present additional phase I data for BGB-3111 in non-Hodgkin's lymphoma, updated Phase 1 data for the combination of BGB-3111 and Gazyva, and initial phase I data for the combination of BGB-3111 and BGB-A317 at the ASH Meeting that is to be held December 9-12, 2017 in Atlanta, GA. -- Initiate phase III trials of BGB-A317 in China in the fourth quarter of 2017 or the first quarter of 2018. -- Initiate a pivotal trial of BGB-290 in China in the fourth quarter of 2017.

2. Aptevo Therapeutics Inc. (APVO)

Gained 15.38% to close Monday's trading at $3.45.

News: No news

You can find more about APVO in our premium stock report. We alerted our premium subscribers to APVO on November 6, 2017 when it was trading around $2.83.

3. Bellerophon Therapeutics Inc. (BLPH)

Gained 8.33% to close Monday's trading at $2.21.

News: No news

Clinical trials & Near-term catalysts:

A phase III program evaluating INOpulse in the treatment of Pulmonary Arterial Hypertension, dubbed INOvation-1, is underway.

Interim analysis and the top-line results for the study are expected to be available in 2018.

A second phase III study of INOpulse in Pulmonary Arterial Hypertension, dubbed INOvation-RW, is planned for initiation in the second half of 2018, with top-line results anticipated in 2019.

A phase IIb study for INOpulse in Idiopathic Pulmonary Fibrosis, called iNO-PF, is expected to commence in early 2018, with readout expected by the end of 2018.

4. Globus Medical Inc. (GMED)

Gained 6.80% to close Monday's trading at $40.18.

News: No news

Recent event:

-- On November 30, 2017, the Company announced results of its seven-year clinical trial follow-up that demonstrated superiority of its SECURE-C Cervical Artificial Disc over the current standard for the treatment of cervical disc disease, anterior cervical discectomy and fusion (ACDF), based on overall success.

The SECURE-C Cervical Artificial Disc was greenlighted by the FDA in October 2012.

-- On November 8, 2017, the Company reported third quarter results and re-affirmed its annual guidance.

The company expects full year 2017 sales of $625 million and non-GAAP EPS of $1.27. Sales were $564.0 million and non-GAAP EPS was $1.19 in 2016.